Skip to main content
Erschienen in: Journal of Endocrinological Investigation 5/2019

01.05.2019 | Review

Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes

verfasst von: D. Giugliano, M. I. Maiorino, G. Bellastella, K. Esposito

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Clinical inertia and medication non-adherence are thought to contribute largely to the suboptimal glycemic control in many patients with type 2 diabetes. The present review explores the relations between A1C targets, clinical inertia and medication non-adherence in type 2 diabetes.

Methods

We searched PubMed for English-language studies published from 2001 through June 1, 2018. We also manually searched the references of selected articles, reviews, meta-analyses, and practice guidelines. Selected articles were mutually agreed upon by the authors.

Results

Clinical inertia is the failure of clinicians to initiate or intensify therapy when indicated, while medication non-adherence is the failure of patients to start or continue therapy that a clinician has recommended. Although clinical inertia may occur at all stages of diabetes treatment, the longest delays were reported for initiation or intensification of insulin. Medication non-adherence to antidiabetic drugs may range from 53 to 65% at 1 year and may be responsible for uncontrolled A1C in about 23% of cases. Reverse clinical inertia can be acknowledged as the failure to reduce or change therapy when no longer needed or indicated. Clinical inertia and medication non-adherence are difficult to address: clinician-and patient-targeted educational programs, more connected communications between clinicians and patients, the help of other health professional figures (nurse, pharmacist) have been explored with mixed results.

Conclusions

Both clinical inertia and medication non-adherence remain significant barriers to optimal glycemic targets in type 2 diabetes. Moreover, part of clinical inertia may be a way through which clinicians face current uncertainty in medicine, including some dissonance among therapeutic guidelines. Scientific associations should find an agreement about how to measure and report clinical inertia in clinical practice and should exhort clinicians to consider reverse clinical inertia as a cause of persisting inappropriate therapy in vulnerable patients.
Literatur
1.
Zurück zum Zitat The US Burden of Disease Collaborators (2018) (2018) The State of US health, 1990–2016 burden of diseases, injuries, and risk factors among US States. JAMA 319:1444–1472CrossRef The US Burden of Disease Collaborators (2018) (2018) The State of US health, 1990–2016 burden of diseases, injuries, and risk factors among US States. JAMA 319:1444–1472CrossRef
2.
Zurück zum Zitat American Diabetes Association (2018) Standards of medical care in diabetes—2018. 6. Glycemic targets. Diabetes Care 41(Suppl 1):S55–S64CrossRef American Diabetes Association (2018) Standards of medical care in diabetes—2018. 6. Glycemic targets. Diabetes Care 41(Suppl 1):S55–S64CrossRef
3.
Zurück zum Zitat Guan X, Zheng L, Sun G et al (2016) The changing relationship between HbA1c and FPG according to different FPG ranges. J Endocrinol Invest 39:523–528CrossRefPubMed Guan X, Zheng L, Sun G et al (2016) The changing relationship between HbA1c and FPG according to different FPG ranges. J Endocrinol Invest 39:523–528CrossRefPubMed
4.
Zurück zum Zitat Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117CrossRefPubMed Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117CrossRefPubMed
5.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
6.
Zurück zum Zitat Gerstein HC, Miller ME, Byington RP et al (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMed Gerstein HC, Miller ME, Byington RP et al (2008) Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMed
7.
Zurück zum Zitat Patel A, MacMahon S, Chalmers J et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed Patel A, MacMahon S, Chalmers J et al (2008) ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMed
8.
Zurück zum Zitat Duckworth W, Abraira C, Moritz T et al (2009) VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed Duckworth W, Abraira C, Moritz T et al (2009) VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139CrossRefPubMed
9.
Zurück zum Zitat Zoungas S, Arima H, Gerstein HC et al (2017) Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Lancet Diabetes Endocrinol 5:431–437CrossRefPubMed Zoungas S, Arima H, Gerstein HC et al (2017) Collaborators on Trials of Lowering Glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomized controlled trials. Lancet Diabetes Endocrinol 5:431–437CrossRefPubMed
10.
Zurück zum Zitat Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298CrossRefPubMed Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288–2298CrossRefPubMed
11.
Zurück zum Zitat Giugliano D, Maiorino MI, Bellastella G, Esposito K (2018) Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine 61:23–27CrossRefPubMed Giugliano D, Maiorino MI, Bellastella G, Esposito K (2018) Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine 61:23–27CrossRefPubMed
12.
Zurück zum Zitat Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 368:1613–1624CrossRefPubMed Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW (2013) Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med 368:1613–1624CrossRefPubMed
13.
Zurück zum Zitat Carls G, Huynh J, Tuttle E, Yee J, Edelman SV (2017) Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther 8:863–873CrossRefPubMedPubMedCentral Carls G, Huynh J, Tuttle E, Yee J, Edelman SV (2017) Achievement of glycated hemoglobin goals in the US remains unchanged through 2014. Diabetes Ther 8:863–873CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Shahraz S, Pittas AG, Saadati M et al (2017) Change in testing, awareness of hemoglobin A1c result, and glycemic control in US Adults, 2007–2014. JAMA 318:1825–1827CrossRefPubMedPubMedCentral Shahraz S, Pittas AG, Saadati M et al (2017) Change in testing, awareness of hemoglobin A1c result, and glycemic control in US Adults, 2007–2014. JAMA 318:1825–1827CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Lipska KJ, Yao X, Herrin J (2017) Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 40:468–475CrossRefPubMed Lipska KJ, Yao X, Herrin J (2017) Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 40:468–475CrossRefPubMed
17.
Zurück zum Zitat de Pablos-Velasco P, Parhofer KG, Bradley C et al (2014) Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 80:47–56CrossRef de Pablos-Velasco P, Parhofer KG, Bradley C et al (2014) Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf) 80:47–56CrossRef
18.
Zurück zum Zitat Willey CJ, Andrade SE, Cohen J et al (2006) Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care 12:435–440PubMed Willey CJ, Andrade SE, Cohen J et al (2006) Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care 12:435–440PubMed
19.
20.
Zurück zum Zitat Giugliano D, Esposito K (2001) 1) Clinical inertia as a clinical safeguard. JAMA 305:1591–1592CrossRef Giugliano D, Esposito K (2001) 1) Clinical inertia as a clinical safeguard. JAMA 305:1591–1592CrossRef
21.
Zurück zum Zitat Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A (2017) Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab 43:501–511CrossRefPubMed Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A (2017) Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab 43:501–511CrossRefPubMed
22.
Zurück zum Zitat Khunti K, Davies MJ (2018) Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes Endocrinol 6:266–268CrossRefPubMed Khunti K, Davies MJ (2018) Clinical inertia versus overtreatment in glycaemic management. Lancet Diabetes Endocrinol 6:266–268CrossRefPubMed
23.
Zurück zum Zitat Chen X, Wu Z, Chen Y et al (2017) Risk score model for type 2 diabetes prediction for rural Chinese adults: the Rural Dequing Cohort Study. Journal Endocrinol Invest 40:1115–1123CrossRef Chen X, Wu Z, Chen Y et al (2017) Risk score model for type 2 diabetes prediction for rural Chinese adults: the Rural Dequing Cohort Study. Journal Endocrinol Invest 40:1115–1123CrossRef
24.
Zurück zum Zitat Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C (2005) Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 28:600–606CrossRefPubMed Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C (2005) Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 28:600–606CrossRefPubMed
25.
Zurück zum Zitat American Diabetes Association (2018) Standards of Medical Care in Diabetes—2018. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 41(Suppl 1):S73–S85CrossRef American Diabetes Association (2018) Standards of Medical Care in Diabetes—2018. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 41(Suppl 1):S73–S85CrossRef
26.
Zurück zum Zitat Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, SOLVE Study Group (2012) Study of once daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 14:654–661CrossRefPubMed Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, SOLVE Study Group (2012) Study of once daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab 14:654–661CrossRefPubMed
27.
Zurück zum Zitat Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36:3411–3417CrossRefPubMedPubMedCentral Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ (2013) Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36:3411–3417CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Escalada J, Orozco-Beltram D, Morillas C et al (2016) Attitude towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research. Diabetes Res Clin Pract 122:46–53CrossRefPubMed Escalada J, Orozco-Beltram D, Morillas C et al (2016) Attitude towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research. Diabetes Res Clin Pract 122:46–53CrossRefPubMed
29.
Zurück zum Zitat Berard L, Bonnemaire M, Mical M, Edelman S (2018) Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. Diabetes Obes Metab 20:301–308CrossRefPubMed Berard L, Bonnemaire M, Mical M, Edelman S (2018) Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey. Diabetes Obes Metab 20:301–308CrossRefPubMed
30.
Zurück zum Zitat Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437CrossRefPubMed Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437CrossRefPubMed
31.
Zurück zum Zitat Pantalone KM, Wells BJ, Chagin KM et al (2016) Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large integrated health system. Diabetes Care 39:1527–1534CrossRefPubMed Pantalone KM, Wells BJ, Chagin KM et al (2016) Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large integrated health system. Diabetes Care 39:1527–1534CrossRefPubMed
32.
Zurück zum Zitat Pantalone KM, Misra-Hebert AD, Hobbs T et al (2018) Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care 41:e113–e114CrossRefPubMed Pantalone KM, Misra-Hebert AD, Hobbs T et al (2018) Clinical inertia in type 2 diabetes management: evidence from a large, real-world data set. Diabetes Care 41:e113–e114CrossRefPubMed
33.
Zurück zum Zitat Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF (2013) Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 51(8 Suppl 3):S11–S21CrossRefPubMedPubMedCentral Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF (2013) Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care 51(8 Suppl 3):S11–S21CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bradley C, Eschwège E, de Pablos-Velasco P et al (2018) Predictors of quality of life and other patient-reported outcomes in the PANORAMA multinational study of people with type 2 diabetes. Diabetes Care 41:267–276CrossRefPubMed Bradley C, Eschwège E, de Pablos-Velasco P et al (2018) Predictors of quality of life and other patient-reported outcomes in the PANORAMA multinational study of people with type 2 diabetes. Diabetes Care 41:267–276CrossRefPubMed
35.
Zurück zum Zitat Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740PubMed Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728–740PubMed
36.
Zurück zum Zitat Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32:725–737CrossRefPubMed Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32:725–737CrossRefPubMed
37.
Zurück zum Zitat McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S (2018) Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 20:1040–1043CrossRefPubMed McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S (2018) Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 20:1040–1043CrossRefPubMed
38.
Zurück zum Zitat Alatorre C, Fernández Landó L, Yu M et al (2017) Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab 19:953–961CrossRefPubMedPubMedCentral Alatorre C, Fernández Landó L, Yu M et al (2017) Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab 19:953–961CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Gordon J, McEwan P, Idris I, Evans M, Puelles J (2018) Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care 6(1):e000512CrossRefPubMedPubMedCentral Gordon J, McEwan P, Idris I, Evans M, Puelles J (2018) Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Res Care 6(1):e000512CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Edelman SV, Polonsky WH (2017) Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 40:1469–1478CrossRefPubMed Edelman SV, Polonsky WH (2017) Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 40:1469–1478CrossRefPubMed
41.
Zurück zum Zitat Gibson TB, Song X, Alemayehu B et al (2010) Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 16:589–600PubMed Gibson TB, Song X, Alemayehu B et al (2010) Cost sharing, adherence, and health outcomes in patients with diabetes. Am J Manag Care 16:589–600PubMed
42.
Zurück zum Zitat Park IS, Sohn HS (2011) Effect of medicine adherence on the occurrence of cerebrovascular disorders in diabetesmellitus patients. Epidemiol Health 33:e2011001CrossRefPubMedPubMedCentral Park IS, Sohn HS (2011) Effect of medicine adherence on the occurrence of cerebrovascular disorders in diabetesmellitus patients. Epidemiol Health 33:e2011001CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Curtis SE, Boye KS, Lage MJ, Garcia-Perez L-E (2017) Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care 23:e208–e214PubMed Curtis SE, Boye KS, Lage MJ, Garcia-Perez L-E (2017) Medication adherence and improved outcomes among patients with type 2 diabetes. Am J Manag Care 23:e208–e214PubMed
44.
Zurück zum Zitat Khunti K, Seidu S, Kunutsor S, Davies M (2017) Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 40:1588–1596CrossRefPubMed Khunti K, Seidu S, Kunutsor S, Davies M (2017) Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 40:1588–1596CrossRefPubMed
46.
Zurück zum Zitat Vrijens B, De Geest S, Hughes DA et al (2012) ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705CrossRefPubMedPubMedCentral Vrijens B, De Geest S, Hughes DA et al (2012) ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Forbes CA, Deshpande S, Sorio-Vilela F et al (2018) A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin 17:1–27 Forbes CA, Deshpande S, Sorio-Vilela F et al (2018) A systematic literature review comparing methods for the measurement of patient persistence and adherence. Curr Med Res Opin 17:1–27
48.
Zurück zum Zitat Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, For the Clinical Guidelines Committee of the American College of Physicians (2018) Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med 168:569–576CrossRef Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA, For the Clinical Guidelines Committee of the American College of Physicians (2018) Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. Ann Intern Med 168:569–576CrossRef
49.
Zurück zum Zitat Pogach L, Aron D (2012) The other side of quality improvement in diabetes for seniors: a proposal for an overtreatment glycemic measure. Arch Intern Med 172:1510–1512CrossRefPubMed Pogach L, Aron D (2012) The other side of quality improvement in diabetes for seniors: a proposal for an overtreatment glycemic measure. Arch Intern Med 172:1510–1512CrossRefPubMed
50.
Zurück zum Zitat Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA (2015) Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 175:356–362CrossRefPubMedPubMedCentral Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA (2015) Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Intern Med 175:356–362CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM (2014) Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 174:259–268CrossRefPubMed Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM (2014) Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 174:259–268CrossRefPubMed
52.
Zurück zum Zitat Riddle MC, Gerstein HC, Holman RR et al (2018) A1C targets should be personalized to maximize benefits while limiting risks. Diabetes Care 41:1121–1124CrossRefPubMed Riddle MC, Gerstein HC, Holman RR et al (2018) A1C targets should be personalized to maximize benefits while limiting risks. Diabetes Care 41:1121–1124CrossRefPubMed
53.
Zurück zum Zitat Tversky A, Kahneman D (1974) Judgment under uncertainty: heuristics and biases. Science 185:1124–1131CrossRefPubMed Tversky A, Kahneman D (1974) Judgment under uncertainty: heuristics and biases. Science 185:1124–1131CrossRefPubMed
54.
Zurück zum Zitat Weber V, Bloom F, Pierdon S, Wood C (2008) Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. J Gen Intern Med 23:379–382CrossRefPubMedPubMedCentral Weber V, Bloom F, Pierdon S, Wood C (2008) Employing the electronic health record to improve diabetes care: a multifaceted intervention in an integrated delivery system. J Gen Intern Med 23:379–382CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Egbunike V, Gerard S (2013) The impact of point-of-care A1C testing on provider compliance and A1C levels in a primary setting. Diabetes Educ 39:66–73CrossRefPubMed Egbunike V, Gerard S (2013) The impact of point-of-care A1C testing on provider compliance and A1C levels in a primary setting. Diabetes Educ 39:66–73CrossRefPubMed
56.
Zurück zum Zitat Cleveringa FG, Gorter KJ, van den Donk M, van Gijsel J, Rutten GE (2013) Computerized decision support systems in primary care for type 2 diabetes patients only improve patients’ outcomes when combined with feedback on performance and case management: a systematic review. Diabetes Technol Ther 15:180–192CrossRefPubMed Cleveringa FG, Gorter KJ, van den Donk M, van Gijsel J, Rutten GE (2013) Computerized decision support systems in primary care for type 2 diabetes patients only improve patients’ outcomes when combined with feedback on performance and case management: a systematic review. Diabetes Technol Ther 15:180–192CrossRefPubMed
57.
Zurück zum Zitat Billue KL, Safford MM, Salanitro AH et al (2012) Medication intensification in diabetes in rural primary care: a cluster-randomised effectiveness trial. BMJ Open 2(5):e000959CrossRefPubMedPubMedCentral Billue KL, Safford MM, Salanitro AH et al (2012) Medication intensification in diabetes in rural primary care: a cluster-randomised effectiveness trial. BMJ Open 2(5):e000959CrossRefPubMedPubMedCentral
58.
Zurück zum Zitat Bieszk N, Reynolds SL, Wei W, Davis C, Kamble P, Uribe C (2016) “Act on Threes” paradigm for treatment intensification of type 2 diabetes in managed care: results of a randomized controlled study with an educational intervention targeting improved glycemic control. J Manag Care Spec Pharm 22:1028–1038PubMed Bieszk N, Reynolds SL, Wei W, Davis C, Kamble P, Uribe C (2016) “Act on Threes” paradigm for treatment intensification of type 2 diabetes in managed care: results of a randomized controlled study with an educational intervention targeting improved glycemic control. J Manag Care Spec Pharm 22:1028–1038PubMed
59.
Zurück zum Zitat Polinski JM, Smith BF, Curtis BH et al (2013) Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ 39:53–65CrossRefPubMed Polinski JM, Smith BF, Curtis BH et al (2013) Barriers to insulin progression among patients with type 2 diabetes: a systematic review. Diabetes Educ 39:53–65CrossRefPubMed
60.
Zurück zum Zitat Strain WD, Cos X, Hirst M et al (2014) Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pr 105:302–312CrossRef Strain WD, Cos X, Hirst M et al (2014) Time to do more: addressing clinical inertia in the management of type 2 diabetes mellitus. Diabetes Res Clin Pr 105:302–312CrossRef
61.
Zurück zum Zitat Garber AJ, Abrahamson MJ, Barzilay JI et al (2018) AACE/ACE Consensus Statement. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract 24:91–120CrossRefPubMed Garber AJ, Abrahamson MJ, Barzilay JI et al (2018) AACE/ACE Consensus Statement. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract 24:91–120CrossRefPubMed
62.
Zurück zum Zitat Furler J, O’Neal D, Speight J et al (2017) Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ 356:j783CrossRefPubMedPubMedCentral Furler J, O’Neal D, Speight J et al (2017) Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ 356:j783CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat van Eikenhorst L, Taxis K, van Dijk L, de Gier H (2017) Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis. Front Pharmacol 8:891CrossRefPubMedPubMedCentral van Eikenhorst L, Taxis K, van Dijk L, de Gier H (2017) Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis. Front Pharmacol 8:891CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Ong SE, Koh JJK, Toh SES et al (2018) Assessing the influence of health systems on type 2 diabetes mellitus awareness, treatment, adherence, and control: a systematic review. PLoS One 13:e0195086CrossRefPubMedPubMedCentral Ong SE, Koh JJK, Toh SES et al (2018) Assessing the influence of health systems on type 2 diabetes mellitus awareness, treatment, adherence, and control: a systematic review. PLoS One 13:e0195086CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat McWilliams JM, Najafzadeh M, Shrank WH, Polinski JM (2017) Association of changes in medication use and adherence with accountable care organization exposure in patients with cardiovascular disease or diabetes JAMA Cardiol 2:1019–1023PubMedPubMedCentral McWilliams JM, Najafzadeh M, Shrank WH, Polinski JM (2017) Association of changes in medication use and adherence with accountable care organization exposure in patients with cardiovascular disease or diabetes JAMA Cardiol 2:1019–1023PubMedPubMedCentral
66.
Zurück zum Zitat Iyengar RN, LeFrancois AL, Henderson RR, Rabbitt RM (2016) Medication nonadherence among medicare beneficiaries with comorbid chronic conditions: influence of pharmacy dispensing channel. J Manag Care Spec Pharm 22:550–560PubMed Iyengar RN, LeFrancois AL, Henderson RR, Rabbitt RM (2016) Medication nonadherence among medicare beneficiaries with comorbid chronic conditions: influence of pharmacy dispensing channel. J Manag Care Spec Pharm 22:550–560PubMed
67.
Zurück zum Zitat de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R (2012) Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev 12:CD007459PubMed de Jongh T, Gurol-Urganci I, Vodopivec-Jamsek V, Car J, Atun R (2012) Mobile phone messaging for facilitating self-management of long-term illnesses. Cochrane Database Syst Rev 12:CD007459PubMed
68.
Zurück zum Zitat Morawski K, Ghazinouri R, Krumme A et al (2018) Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP Randomized Clinical Trial. JAMA Intern Med 178:802–809CrossRefPubMedPubMedCentral Morawski K, Ghazinouri R, Krumme A et al (2018) Association of a smartphone application with medication adherence and blood pressure control: the MedISAFE-BP Randomized Clinical Trial. JAMA Intern Med 178:802–809CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Hou C, Carter B, Hewitt J, Francisa T, Mayor S (2016) Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials. Diabetes Care 39:2089–2095CrossRefPubMed Hou C, Carter B, Hewitt J, Francisa T, Mayor S (2016) Do mobile phone applications improve glycemic control (HbA1c) in the self-management of diabetes? A systematic review, meta-analysis, and GRADE of 14 randomized trials. Diabetes Care 39:2089–2095CrossRefPubMed
70.
Zurück zum Zitat Kleinman NJ, Shah A, Shah S, Phatak S, Viswanathan V (2017) Improved medication adherence and frequency of blood glucose self-testing using an m-Health platform versus usual care in a multisite randomized clinical trial among people with type 2 diabetes in India. Telemed J E Health 23:733–740CrossRefPubMed Kleinman NJ, Shah A, Shah S, Phatak S, Viswanathan V (2017) Improved medication adherence and frequency of blood glucose self-testing using an m-Health platform versus usual care in a multisite randomized clinical trial among people with type 2 diabetes in India. Telemed J E Health 23:733–740CrossRefPubMed
72.
Zurück zum Zitat Giugliano D, Maiorino MI, Bellastella G, Esposito K (2017) Comment on Edelman and Polonsky. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40:1425–1432. Diabetes Care 41:e17CrossRef Giugliano D, Maiorino MI, Bellastella G, Esposito K (2017) Comment on Edelman and Polonsky. Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40:1425–1432. Diabetes Care 41:e17CrossRef
73.
Zurück zum Zitat Qaseem A, Barry MJ, Humphrey LL, Forciea MA; for the Clinical Guidelines Committee of the American College of Physicians (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:279–290CrossRef Qaseem A, Barry MJ, Humphrey LL, Forciea MA; for the Clinical Guidelines Committee of the American College of Physicians (2017) Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:279–290CrossRef
75.
Zurück zum Zitat Cabana MD, Rand CS, Powe NR et al (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458–1465CrossRefPubMed Cabana MD, Rand CS, Powe NR et al (1999) Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 282:1458–1465CrossRefPubMed
76.
Zurück zum Zitat (2011) Guiding the guidelines. Lancet 377:1125 (2011) Guiding the guidelines. Lancet 377:1125
77.
Zurück zum Zitat Zinman B, Wanner C, Lachin JM et al (2015) EMPA-REG OUTCOME investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed Zinman B, Wanner C, Lachin JM et al (2015) EMPA-REG OUTCOME investigators, empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRefPubMed
78.
Zurück zum Zitat Marso SP, Daniels GH, Brown-Frandsen K et al (2016) LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322CrossRefPubMedPubMedCentral Marso SP, Daniels GH, Brown-Frandsen K et al (2016) LEADER Trial Investigators, Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322CrossRefPubMedPubMedCentral
79.
Zurück zum Zitat Marso SP, Bain SC, Consoli A et al (2016) SUSTAIN-6 Investigators, semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844CrossRefPubMed Marso SP, Bain SC, Consoli A et al (2016) SUSTAIN-6 Investigators, semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844CrossRefPubMed
80.
Zurück zum Zitat Neal B, Perkovic V, Mahaffey KW et al (2017) CANVAS Program Collaborative Group, canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657CrossRefPubMed Neal B, Perkovic V, Mahaffey KW et al (2017) CANVAS Program Collaborative Group, canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657CrossRefPubMed
Metadaten
Titel
Clinical inertia, reverse clinical inertia, and medication non-adherence in type 2 diabetes
verfasst von
D. Giugliano
M. I. Maiorino
G. Bellastella
K. Esposito
Publikationsdatum
01.05.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 5/2019
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0951-8

Weitere Artikel der Ausgabe 5/2019

Journal of Endocrinological Investigation 5/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.